Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free RLMD Stock Alerts

Relmada Therapeutics (RLMD) Financials

Relmada Therapeutics logo
$7.42 -0.07 (-0.93%)
Closing price 04:00 PM Eastern
Extended Trading
$7.42 +0.00 (+0.07%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Relmada Therapeutics

Annual Income Statements for Relmada Therapeutics

This table shows Relmada Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -21 -2.97 -6.29 -15 -59 -126 -157 -99 -80 -57
Consolidated Net Income / (Loss)		 -21 -2.97 -6.29 -15 -59 -126 -157 -99 -80 -57
Net Income / (Loss) Continuing Operations		 -21 -2.97 -6.29 -15 -59 -125 -159 -99 -80 -57
Total Pre-Tax Income 		-21 -2.97 -6.29 -15 -59 -125 -159 -99 -80 -57
Total Operating Income		 -17 -16 -7.22 -15 -61 -126 -161 -104 -84 -59
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 16 7.22 15 61 126 161 104 84 59
Selling, General & Admin Expense		 9.23 10 5.93 7.25 25 35 48 49 38 32
Research & Development Expense		 7.87 6.21 1.29 7.86 36 91 113 55 46 27
Total Other Income / (Expense), net		 -3.70 13 0.93 0.10 1.38 1.20 2.64 4.91 3.91 1.72
Interest & Investment Income		 - - - - - - - 5.15 3.53 1.40
Other Income / (Expense), net		 -3.71 13 0.93 0.00 -0.02 0.00 -0.02 -0.24 0.38 0.32
Basic Earnings per Share		 ($2.09) ($0.26) ($0.52) ($1.62) ($3.81) ($7.16) ($5.30) ($3.28) ($2.65) ($1.45)
Weighted Average Basic Shares Outstanding		 9.94M 11.60M 12.07M 9.24M 15.59M 17.55M 29.63M 30.10M 30.16M 39.48M
Diluted Earnings per Share		 ($2.09) ($0.26) ($0.52) ($1.62) ($3.81) - - ($3.28) ($2.65) ($1.45)
Weighted Average Diluted Shares Outstanding		 9.94M 11.60M 12.07M 9.24M 15.59M 17.55M 30.10M 30.10M 30.16M 39.48M

Quarterly Income Statements for Relmada Therapeutics

This table shows Relmada Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -22 -25 -22 -18 -22 -19 -18 -9.87 -10 -20 -19
Consolidated Net Income / (Loss)		 -22 -25 -22 -18 -22 -19 -18 -9.87 -10 -20 -19
Net Income / (Loss) Continuing Operations		 -22 -25 -22 -18 -22 -19 -18 -9.87 -10 -20 -19
Total Pre-Tax Income 		-22 -25 -22 -18 -22 -19 -18 -9.87 -10 -20 -19
Total Operating Income		 -23 -27 -23 -19 -23 -19 -18 -10 -10 -20 -19
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 23 27 23 19 23 19 18 10 10 20 19
Selling, General & Admin Expense		 12 12 9.68 8.10 12 8.08 6.27 7.40 6.29 12 11
Research & Development Expense		 10 15 13 11 11 11 12 2.82 4.04 8.07 8.09
Total Other Income / (Expense), net		 0.69 1.66 1.16 1.05 1.28 0.42 0.66 0.35 0.24 0.47 0.41
Interest & Investment Income		 1.32 1.26 1.06 0.96 0.86 0.65 0.44 0.32 0.25 0.39 0.96
Other Income / (Expense), net		 -0.63 0.40 0.10 0.09 0.43 -0.24 0.22 0.03 -0.01 0.08 -0.55
Basic Earnings per Share		 ($0.73) ($0.84) ($0.72) ($0.59) ($0.72) ($0.62) ($0.58) ($0.30) ($0.30) ($0.27) ($0.22)
Weighted Average Basic Shares Outstanding		 30.10M 30.10M 30.13M 30.17M 30.17M 30.16M 30.41M 33.19M 33.19M 39.48M 86.60M
Diluted Earnings per Share		 ($0.73) - ($0.72) ($0.59) ($0.72) ($0.62) ($0.58) ($0.30) ($0.30) ($0.27) ($0.22)
Weighted Average Diluted Shares Outstanding		 30.10M 30.10M 30.13M 30.17M 30.17M 30.16M 30.41M 33.19M 33.19M 39.48M 86.60M

Annual Cash Flow Statements for Relmada Therapeutics

This table details how cash moves in and out of Relmada Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.09 -14 -6.79 6.98 -34 42 -39 -1.30 -0.23 -0.36
Net Cash From Operating Activities		 -16 -13 -6.47 -10 -28 -92 -104 -52 -52 -46
Net Cash From Continuing Operating Activities		 -16 -13 -6.47 -10 -28 -92 -104 -52 -52 -46
Net Income / (Loss) Continuing Operations		 -21 -2.97 -6.29 -17 -59 -126 -157 -99 -80 -57
Consolidated Net Income / (Loss)		 -21 -2.97 -6.29 -17 -59 -126 -157 -99 -80 -57
Non-Cash Adjustments To Reconcile Net Income		 1.98 -12 0.70 4.59 21 42 43 44 30 16
Changes in Operating Assets and Liabilities, net		 2.59 1.68 -0.96 1.56 11 -7.86 11 3.08 -1.58 -3.95
Net Cash From Investing Activities		 -0.02 -0.56 -0.05 0.00 -34 -54 20 50 52 -48
Net Cash From Continuing Investing Activities		 -0.02 -0.56 -0.05 0.00 -34 -54 20 50 52 -48
Purchase of Investments		 - - - - -182 -223 -47 -90 -12 -84
Sale and/or Maturity of Investments		 - - - - 148 169 67 141 64 36
Net Cash From Financing Activities		 13 -0.26 -0.27 17 28 188 45 -0.10 -0.04 94
Net Cash From Continuing Financing Activities		 13 -0.26 -0.27 17 28 188 45 -0.10 -0.04 94
Repurchase of Common Equity		 - - - - - - - -0.10 -0.29 -0.07
Issuance of Common Equity		 0.03 - - 18 20 188 43 0.00 0.00 94
Other Financing Activities, net		 13 - - 0.00 8.79 0.00 2.34 - 0.25 0.00

Quarterly Cash Flow Statements for Relmada Therapeutics

This table details how cash moves in and out of Relmada Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -7.77 -2.61 -2.76 0.75 -0.60 2.37 -2.71 0.20 0.03 2.11 6.28
Net Cash From Operating Activities		 -12 -10 -13 -13 -17 -8.80 -18 -6.40 -6.72 -15 -15
Net Cash From Continuing Operating Activities		 -12 -10 -13 -13 -17 -8.80 -18 -6.40 -6.72 -15 -15
Net Income / (Loss) Continuing Operations		 -22 -25 -22 -18 -22 -19 -18 -9.87 -10 -20 -19
Consolidated Net Income / (Loss)		 -22 -25 -22 -18 -22 -19 -18 -9.87 -10 -20 -19
Non-Cash Adjustments To Reconcile Net Income		 12 9.49 8.19 7.13 7.82 6.67 4.26 3.42 4.05 3.83 4.18
Changes in Operating Assets and Liabilities, net		 -1.65 5.43 0.60 -2.62 -2.75 3.19 -4.77 0.05 -0.68 1.45 -0.20
Net Cash From Investing Activities		 3.86 7.74 10 14 16 11 15 6.68 6.75 -77 -135
Net Cash From Continuing Investing Activities		 3.86 7.74 10 14 16 11 15 6.68 6.75 -77 -135
Purchase of Investments		 -12 -33 -7.01 -1.30 -3.11 -0.65 -0.49 -0.32 -0.23 -83 -150
Sale and/or Maturity of Investments		 15 41 17 15 19 12 16 7.00 6.99 5.86 14
Net Cash From Financing Activities		 - -0.10 0.22 - -0.09 -0.17 0.00 -0.07 - 94 157
Net Cash From Continuing Financing Activities		 - -0.10 0.22 - -0.09 -0.17 0.00 -0.07 - 94 157
Repurchase of Common Equity		 - - -0.03 - - - 0.00 - - - -3.43
Other Financing Activities, net		 - - 0.25 - - - 0.00 - - - 160

Annual Balance Sheets for Relmada Therapeutics

This table presents Relmada Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2014 6/30/2015 6/30/2016 6/30/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 26 24 10 2.84 117 118 223 153 98 46 94
Total Current Assets		 26 24 9.30 2.47 117 118 223 153 98 46 94
Cash & Equivalents		 26 22 8.50 1.71 36 2.50 - 5.40 4.09 3.86 3.50
Short-Term Investments		 - - - - 80 115 167 143 92 41 90
Prepaid Expenses		 0.18 1.50 0.57 0.47 0.42 0.90 11 4.04 1.19 0.89 0.98
Plant, Property, & Equipment, net		 0.01 0.02 0.53 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.01 0.40 0.41 0.36 0.19 0.11 0.03 0.03 0.04 0.02 0.02
Other Noncurrent Operating Assets		 0.01 0.40 0.41 0.02 0.03 0.03 0.03 0.03 0.04 0.02 0.02
Total Liabilities & Shareholders' Equity		 26 24 10 2.84 117 118 223 153 98 46 94
Total Liabilities		 27 16 3.20 1.38 1.46 13 15 12 12 10 7.49
Total Current Liabilities		 27 16 3.06 1.38 1.46 13 15 12 12 10 6.43
Accounts Payable		 0.75 0.84 1.26 0.53 0.52 8.35 11 5.26 3.51 4.13 1.57
Accrued Expenses		 0.38 0.48 0.63 0.39 0.82 4.26 3.87 7.21 8.69 6.16 4.86
Total Noncurrent Liabilities		 0.10 0.00 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.06
Other Noncurrent Operating Liabilities		 0.10 0.00 0.14 - - - - - 0.00 0.00 1.06
Commitments & Contingencies		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.11 8.81 7.04 1.46 116 106 208 140 85 36 87
Total Preferred & Common Equity		 -1.11 8.81 7.04 1.46 116 106 208 140 85 36 87
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 - - 0.00 0.00 0.00 0.00
Total Common Equity		 -1.11 8.81 7.04 1.46 116 106 208 140 85 36 87
Common Stock		 54 85 86 87 236 285 513 603 646 676 785
Retained Earnings		 -55 -76 -79 -85 -120 -179 -305 -462 -561 -641 -698

Quarterly Balance Sheets for Relmada Therapeutics

This table presents Relmada Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 122 109 84 71 56 28 21 15 235
Total Current Assets		 122 109 84 71 56 28 21 15 235
Cash & Equivalents		 14 6.70 1.34 2.09 1.48 1.15 1.35 1.38 9.78
Short-Term Investments		 104 100 82 68 53 26 19 13 224
Prepaid Expenses		 3.47 2.83 0.75 0.54 1.58 0.60 0.47 0.97 1.38
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.03 0.05 0.04 0.05 0.02 0.02 0.02 0.02 0.02
Other Noncurrent Operating Assets		 0.03 0.05 0.04 0.05 0.02 0.02 0.02 0.02 0.02
Total Liabilities & Shareholders' Equity		 122 109 84 71 56 28 21 15 235
Total Liabilities		 11 8.42 12 9.54 8.10 5.24 5.17 5.41 17
Total Current Liabilities		 11 8.42 12 9.54 8.09 5.23 5.13 5.19 13
Accounts Payable		 4.85 2.86 5.19 4.17 2.35 1.27 1.36 1.45 5.73
Accrued Expenses		 5.85 5.57 7.17 5.36 5.74 3.97 3.77 3.74 7.16
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.22 3.74
Other Noncurrent Operating Liabilities		 - - - - 0.01 0.01 - 0.22 3.74
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 111 101 72 61 48 22 16 9.47 219
Total Preferred & Common Equity		 111 101 72 61 48 22 16 9.47 219
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 111 101 72 61 48 22 16 9.47 219
Common Stock		 625 636 655 662 670 681 684 688 936
Retained Earnings		 -514 -536 -583 -600 -622 -658 -668 -678 -717

Annual Metrics And Ratios for Relmada Therapeutics

This table displays calculated financial ratios and metrics derived from Relmada Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 53,743,024.00 12,019,162.00 12,039,912.00 12,548,870.00 33,256,987.00 16,241,526.00 17,530,830.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00
DEI Adjusted Shares Outstanding		 53,743,024.00 12,019,162.00 12,039,912.00 12,548,870.00 33,256,987.00 16,241,526.00 17,530,830.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.39 -0.25 -0.52 - -0.52 -3.66 -7.17 -5.22 -3.28 -2.66 -1.91
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -12 -11 -5.05 -4.84 -8.91 -43 -88 -113 -73 -59 -41
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -85.04% -165.32% -47.82%
Earnings before Interest and Taxes (EBIT)		 -21 -2.98 -6.29 -7.62 -13 -61 -126 -161 -104 -84 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -2.92 -6.20 -6.59 -13 -61 -126 -161 -104 -84 -59
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -24 -6.26 -0.01 -13 -32 -96 -109 -70 -60 -44
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -13 -1.18 0.03 -4.81 -0.65 -12 -3.73 -7.89 -11 -9.39 -6.49
Increase / (Decrease) in Invested Capital		 13 12 1.21 -4.84 4.16 -11 7.78 -4.16 -3.08 1.58 2.89
Book Value per Share		 $0.16 $0.59 $0.12 ($0.44) $3.48 $6.50 $11.88 $4.67 $2.84 $1.18 $2.19
Tangible Book Value per Share		 $0.16 $0.59 $0.12 ($0.44) $3.48 $6.50 $11.88 $4.67 $2.84 $1.18 $2.19
Total Capital		 9.07 7.32 1.74 -2.57 116 106 208 140 85 36 87
Total Debt		 0.26 0.27 0.28 2.94 0.11 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 2.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -22 -8.23 -1.43 0.70 -116 -117 -167 -148 -96 -45 -93
Capital Expenditures (CapEx)		 0.02 0.56 0.05 0.01 85 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -14 -1.99 -0.34 -5.12 -0.85 -12 41 -7.92 -11 -9.40 -5.45
Debt-free Net Working Capital (DFNWC)		 8.65 6.51 1.37 -2.88 116 105 208 140 85 36 88
Net Working Capital (NWC)		 8.39 6.24 1.10 -3.17 115 105 208 140 85 36 88
Net Nonoperating Expense (NNE)		 8.83 -8.38 1.23 4.12 8.41 17 38 44 26 21 16
Net Nonoperating Obligations (NNO)		 -22 -8.23 -1.43 0.70 -116 -117 -212 -148 -96 -45 -93
Total Depreciation and Amortization (D&A)		 0.01 0.05 0.09 1.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.09) ($0.26) ($0.52) ($0.71) ($0.69) ($3.81) ($7.16) ($5.30) ($3.28) ($2.65) ($1.45)
Adjusted Weighted Average Basic Shares Outstanding		 10.81M 12.04M 12.55M 12.60M 39.58M 16.75M 29.37M 29.63M 30.10M 30.16M 39.48M
Adjusted Diluted Earnings per Share		 ($2.09) ($0.26) ($0.52) ($0.71) ($0.69) ($3.81) ($7.16) $0.00 $0.00 ($2.65) ($1.45)
Adjusted Weighted Average Diluted Shares Outstanding		 10.81M 12.04M 12.55M 12.60M 39.58M 16.75M 29.37M 30.10M 30.17M 30.16M 39.48M
Adjusted Basic & Diluted Earnings per Share		 ($2.09) ($0.26) ($0.52) ($0.71) ($0.69) ($3.81) ($7.16) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 9.94M 11.60M 12.07M 12.55M 25.25M 15.59M 17.55M 30.10M 30.17M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -11 -5.05 -4.84 -8.91 -43 -88 -113 -73 -59 -41
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Relmada Therapeutics

This table displays calculated financial ratios and metrics derived from Relmada Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00
DEI Adjusted Shares Outstanding		 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00 30,099,203.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.73 -0.84 -0.73 -0.59 -0.72 -0.62 -0.58 -0.33 -0.34 -0.66 -0.63
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 42.05% 34.91% 16.87% 29.76% 3.18% 26.92% 21.34% 45.61% 54.22% - -11.18%
EBIT Growth		 42.05% 34.91% 16.87% 29.76% 3.18% 26.92% 21.34% 45.61% 54.22% - -11.18%
NOPAT Growth		 41.42% 30.68% 18.35% 27.69% -1.39% 28.90% 20.75% 45.69% 55.12% - -6.82%
Net Income Growth		 44.18% 33.68% 17.07% 29.78% 1.25% 25.86% 19.56% 44.47% 53.55% - -8.50%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 1.37% 0.00% 19.44% 49.15% 58.33% - 62.07%
Operating Cash Flow Growth		 56.70% 71.44% 21.01% 0.08% -43.21% 14.15% -38.59% 51.73% 59.64% - 16.60%
Free Cash Flow Firm Growth		 -13.93% 31.55% 49.98% 56.29% 46.17% 4.89% -71.32% -0.09% 38.63% - 84.70%
Invested Capital Growth		 68.89% -39.06% -65.88% -24.36% -17.18% 14.40% 60.05% 47.80% 31.91% - -229.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 12.54% -13.30% 13.40% 18.15% -20.56% 14.48% 6.79% 43.40% -1.48% - 1.20%
EBIT Q/Q Growth		 12.54% -13.30% 13.40% 18.15% -20.56% 14.48% 6.79% 43.40% -1.48% - 1.20%
NOPAT Q/Q Growth		 12.81% -18.23% 14.32% 18.14% -22.27% 17.09% 4.49% 43.90% -1.04% - 4.29%
Net Income Q/Q Growth		 13.05% -14.38% 13.26% 18.60% -22.28% 14.13% 5.88% 43.81% -2.28% - 4.11%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 18.06% -22.03% 0.00% 0.00% 48.28% 0.00% - 18.52%
Operating Cash Flow Q/Q Growth		 12.37% 11.88% -27.19% -1.74% -25.59% 47.17% -105.32% 64.57% -5.00% - -3.23%
Free Cash Flow Firm Q/Q Growth		 -7.74% 44.23% 26.77% 0.67% -32.69% 1.47% -31.92% 41.97% 18.63% - 82.41%
Invested Capital Q/Q Growth		 22.98% -97.94% -5.47% 22.66% 27.42% -44.59% 50.78% -1.07% 5.33% - -134.52%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 94.33% 95.23% 95.39% 94.86% 96.21% 96.61% 97.55% 96.84% 97.61% - 95.20%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -83.55% -87.51% -95.48% -100.40% -116.60% -132.33% -160.26% -175.12% -196.79% - -48.83%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -83.55% -87.51% -95.48% -100.40% -116.60% -132.33% -160.26% -175.12% -196.79% - -48.83%
Return on Equity Simple (ROE_SIMPLE)		 -110.77% 0.00% -130.89% 0.00% 0.00% 0.00% -337.38% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -19 -16 -13 -16 -13 -13 -7.15 -7.23 -14 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.21% -5.22% -5.31% -4.86% -7.01% -7.51% -8.69% -5.96% -8.42% - -4.16%
Return On Investment Capital (ROIC_SIMPLE)		 - -22.00% -22.33% -21.42% -33.82% -37.59% -56.83% -44.86% -76.37% -16.45% -6.23%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -23 -26 -23 -19 -23 -19 -18 -10 -10 -20 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 -26 -23 -19 -23 -19 -18 -10 -10 -20 -20
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.90 1.46 1.94 1.47 2.05 0.44 0.37 1.25 7.05 - 2.76
Price to Tangible Book Value (P/TBV)		 0.90 1.46 1.94 1.47 2.05 0.44 0.37 1.25 7.05 - 2.76
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.09 -1.08 -1.09 -1.09 -1.08 -1.17 -1.17 -1.18 -1.19 - -1.08
Leverage Ratio		 1.11 1.11 1.11 1.12 1.11 1.19 1.19 1.19 1.24 - 1.09
Compound Leverage Factor		 1.05 1.06 1.06 1.06 1.07 1.15 1.16 1.15 1.21 - 1.04
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -0.04 -1.76 -2.74 -5.97 -8.70 -19.13 -33.54 -42.68 -57.96 - 18.33
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.95 8.00 6.82 7.44 6.89 4.45 5.29 4.11 2.86 - 18.26
Quick Ratio		 12.62 7.90 6.76 7.39 6.69 4.36 5.17 4.02 2.68 - 18.15
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -28 -16 -11 -11 -15 -15 -20 -11 -9.30 -17 -3.01
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.54 -11 -12 -8.95 -6.49 -9.39 -4.62 -4.67 -4.42 -6.49 -15
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 12 -3.08 -4.59 -1.75 -0.95 1.58 6.95 4.28 2.07 2.89 -11
Enterprise Value (EV)		 -16 28 57 20 44 -29 -19 -0.69 53 - 369
Market Capitalization		 90 125 140 91 98 16 8.21 20 67 - 603
Book Value per Share		 $3.35 $2.84 $2.39 $2.04 $1.58 $1.18 $0.74 $0.48 $0.29 $2.19 $2.53
Tangible Book Value per Share		 $3.35 $2.84 $2.39 $2.04 $1.58 $1.18 $0.74 $0.48 $0.29 $2.19 $2.53
Total Capital		 101 85 72 61 48 36 22 16 9.47 87 219
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -106 -96 -84 -70 -54 -45 -27 -21 -14 -93 -234
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.59 -11 -12 -9.00 -6.50 -9.40 -4.64 -4.66 -4.22 -5.45 -12
Debt-free Net Working Capital (DFNWC)		 101 85 72 61 48 36 22 16 9.66 88 222
Net Working Capital (NWC)		 101 85 72 61 48 36 22 16 9.66 88 222
Net Nonoperating Expense (NNE)		 6.12 6.38 5.74 4.59 5.62 5.30 4.81 2.71 2.86 5.63 5.43
Net Nonoperating Obligations (NNO)		 -106 -96 -84 -70 -54 -45 -27 -21 -14 -93 -234
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.73) ($0.84) ($0.72) ($0.59) ($0.72) ($0.62) ($0.58) ($0.30) ($0.30) ($0.27) ($0.22)
Adjusted Weighted Average Basic Shares Outstanding		 30.10M 30.10M 30.13M 30.17M 30.17M 30.16M 30.41M 33.19M 33.19M 39.48M 86.60M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.72) ($0.62) ($0.58) ($0.30) ($0.30) ($0.27) ($0.22)
Adjusted Weighted Average Diluted Shares Outstanding		 30.10M 30.10M 30.17M 30.17M 30.17M 30.16M 30.41M 33.19M 33.19M 39.48M 86.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 30.10M 30.17M 30.17M 30.17M 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -19 -16 -13 -16 -13 -13 -7.15 -7.23 -14 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% -0.10% 0.00% 0.00% 0.00% -0.36% -0.35% 0.00% 0.00% - -5.94%

Financials Breakdown Chart

Key Financial Trends

Below is a concise, evidence-based snapshot of Relmada Therapeutics (NASDAQ: RLMD) drawn from quarterly statements over the last four years. The company has yet to report meaningful product revenue in the periods shown and continues to run operating losses, but there are notable liquidity developments in late 2025 thanks to a large equity financing event.

  • Large equity financing in 4Q2025: Issuance of Common Equity for about $93.71 million, with net cash from financing activities around $93.64 million, helping shore up liquidity.
  • Improved near-term liquidity from financing: Net Change in Cash & Equivalents in 4Q2025 was about $2.11 million, supported by the strong financing inflow.
  • Liquidity in late 2025 shows positive quarterly cash movements: Net Change in Cash & Equivalents was +$203,645 in Q2 2025, +$31,133 in Q3 2025, and +$2,112,056 in Q4 2025, indicating improving liquidity tailwinds through 2025.
  • Relatively modest liabilities versus assets in late 2025: For example, in Q3 2025 Total Liabilities were about $5.41 million while Total Assets were about $14.88 million, suggesting a cushion for near-term obligations.
  • No revenue yet in multiple quarters: Total Revenue is 0.0 in several periods (e.g., Q3 2025, Q2 2025, Q1 2025), indicating the company is not generating product sales yet.
  • Ongoing operating cash burn despite liquidity inflows: Net Cash From Continuing Operating Activities is negative in several quarters (e.g., Q4 2025: -$14,596,223; Q3 2025: -$6,721,856; Q1 2025: -$18,067,033), showing persistent cash burn relative to cash inflows.
  • Pulse of earnings per share remains negative, with no positive quarterly earnings per share: 2025 Q4 Basic EPS and Diluted EPS are -$0.27; 2025 Q3 -$0.30; 2025 Q1 -$0.58 (and similar negative values in other recent quarters).
  • Material net losses persist: Net Income / Loss remains negative across the observed quarters (e.g., 2025 Q4 Net Income: -$19,867,760; 2025 Q3: -$10,091,496; 2025 Q2: -$9,866,442; 2025 Q1: -$17,559,465).
  • Ongoing substantial operating expenses drive losses: In 4Q2025, total operating expenses were about $20.33 million (SG&A ~$12.26M + R&D ~$8.07M), contributing to a negative pre-tax income of around -$19.87 million and losses to the bottom line.
  • Reliance on financing to fund operations: The 4Q2025 financing spike underscores a pattern of funding operations through equity activity rather than operating cash flow, which can dilute existing shareholders and increase capital-raising risk.
05/14/26 05:25 PM ETAI Generated. May Contain Errors.

Relmada Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Relmada Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Relmada Therapeutics' net income appears to be on an upward trend, with a most recent value of -$57.39 million in 2025, rising from -$20.80 million in 2015. The previous period was -$79.98 million in 2024. Find out what analysts predict for Relmada Therapeutics in the coming months.

Relmada Therapeutics' total operating income in 2025 was -$59.10 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $59.10 million

Over the last 9 years, Relmada Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Relmada Therapeutics' total liabilities were at $7.49 million at the end of 2025, a 27.2% decrease from 2024, and a 72.1% decrease since 2014.

In the past 10 years, Relmada Therapeutics' cash and equivalents has ranged from $0.00 in 2021 to $36.28 million in 2019, and is currently $3.50 million as of their latest financial filing in 2025.

Over the last 10 years, Relmada Therapeutics' book value per share changed from 0.16 in 2015 to 2.19 in 2025, a change of 1,237.0%.


Related Companies

Financial statements for NASDAQ:RLMD last updated on 5/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Trump is positioned. Elon lights the fuse.
Bitcoin is back above $80,000. Altcoins are pumping. ETF inflows are accelerating. The CLARITY Act… the most b...
Crypto 101 Media | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel